Immutep Limited (ASX:IMM) Investor Presentation
Immutep Limited CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint and pipeline, eftilagimod alpha’s potential, and ongoing clinical trials.
Read MoreBiotechnology
Chimeric Therapeutics (ASX:CHM) Expands Cancer Trials
Chimeric Therapeutics CEO / MD Jennifer Chow provides an update on clinical trial progression and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.
Read MoreRadiopharm Theranostics: Developing a portfolio of assets targeting cancer
Radiopharm Theranostics Limited CEO and Managing Director Riccardo Canevari provides an update on the company’s pipeline and discusses the recent licensing of an asset from UCLA.
Read MoreSuperbugs Are Outsmarting Antibiotics
As Magellan Investment Specialist Michael Collins explains, a market failure means pharmaceutical companies are failing to address the threat of increasingly drug-resistant “Superbugs”.
Read MoreHow Immutep Treats Head & Neck Cancer
ShareCafe spoke with Marc Voigt, CEO of local biotech Immutep, about the progress his company is making specifically in the area of head and neck cancer treatments.
Read MoreKey Points To Remember When Investing in Biotech Companies
As part of his latest research report on the biotech sector, Corporate Connect analyst Marc Sinatra gives some insights into what to consider when making an investment in this space.
Read MoreCustody Battle Drags on for Virtus Health
The battle for IVF operator Virtus continues, with Australian private equity group BGH upping its offer price to $7.65 per share as it goes head-to-head with London based rival CapVest.
Read MoreNovartis, US Political Risks and Investing in Cancer Research
Magellan’s John Wylie reviews Novartis, looks at US political risks to the healthcare sector, and addresses how cancer research innovation may translate to investment profits.
Read MoreBuying Opportunities Beckon Amid Biotech Bloodbath
The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising rates, dwindling liquidity and heightened geopolitical tensions.
Read MoreDrug Pricing and Impact Investing
The issue of drug pricing is not straightforward. The common perception of ’evil pharma’ or governments attacking innovation is unhelpful and oversimplifies a complex challenge.
Read MoreAntisense Therapeutics: The pathway to commercialisation
Corporate Connect analyst Marc Sinatra has released a comprehensive research report on Antisense Therapeutics (ASX: ANP), placing a 12-month target on the company of $0.55 per share.
Read MoreWhat Has Happened to Biotech?
After coronavirus vaccines made biotech the standout performer in 2020, the sector has faced a major reckoning this year, leaving many investors wondering why.
Read MoreLatest from Immutep (ASX: IMM) on LAG-3 and 2022 Outlook
The attached video covers biotech company Immutep’s latest news on their Lymphocyte Activation Gene-3 (LAG-3) treatment and outlook for the coming 12 months.
Read MoreCSL Finally Confirms $A16 Billion Vifor Deal
CSL announced late Tuesday that it has struck a deal to buy Swiss-based Vifor Pharma Ltd for $A16.4 billion, its biggest deal since listing in 1994.
Read MoreCSL Confirms Vifor Talks
After weeks of speculation that CSL was looking to bid for Swiss pharma firm Vifor, the companies have today confirmed they are in talks.
Read MoreVariants Could Extend Growth Curve for Vaccine Makers
The need to safeguard the health of large populations continues to create opportunities that leverage the innovation of biopharmaceutical and lifescience tools manufacturers.
Read MoreModelling the Metaverse: The Fight to Profit from the Next Big Thing
What has long been a subject of science fiction—a totally immersive virtual world inhabited by all of humanity—is increasingly a part of Big Tech companies’ plans for future growth. And the winner is…
Read MoreDue Diligence Webinar – Antisense Therapeutics (ASX: ANP)
In a first time exclusive hear from Antisense Therapeutics (ASX: ANP) Managing Director & CEO – Mark Diamond, Chair – Charmaine Gittleson & Non-Executive Director – Gill Price.
Read MoreA Healthy Dose of Optimism
GAM Investments’ Jenna Denyes reviews some encouraging recent developments as the biotech and pharmaceutical industries continue to make impressive progress against Covid-19.
Read MoreDue Diligence Webinar – Kazia Therapeutics
Presenter – James Garner CEO & Managing Director – Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company based in Sydney, Australia. Kazia’s pipeline includes two clinical-stage drug development candidates and is working to develop therapies across a range of oncology indications.
Read MoreOne-on-One with Platinum’s Dr Bianca Ogden
Platinum’s resident virologist and portfolio manager Dr Bianca Ogden chats with Douglas Isles on how increased funding and computing power is transforming the healthcare sector.
Read MoreQ&A with Perpetual’s Thomas Rice
Perpetual portfolio manager Thomas Rice takes us through the sectors he currently likes, key trends ahead for innovation investment and a ‘truly transformational’ US disruptor.
Read MoreDiagnosing COVID Via a Smartphone App
ResApp Health (ASX: RAP) is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
Read MoreImmutep Taking the Fight to Cancer
Following on from his previous report on the company, Corporate Connect analyst Marc Sinatra has today published an updated analysis of ASX-listed biotech Immutep Ltd (ASX: IMM), valuing IMM at $A2.20 per share.
Read MoreAntisense Duchenne’s Trial Set for Approval?
Corporate Connect analyst Marc Sinatra has released an update of his previous research report on Antisense Therapeutics, placing a 12-month price target on the company of $A0.48.
Read MoreThe Three Drivers of Innovation in Biotech Stocks
In this video, John Hall from T. Rowe Price looks at the three drivers of innovation in the biotech industry that are creating investment opportunities that will help shape the future of medicine.
Read MoreImmutep Leading the development of immunotherapy for cancer and autoimmune diseases
Pengana Fund manager James McDonald provides insight into why he believes biotech Immutep is very well placed to benefit from the current environment and how it fits in the portfolio structure.
Read More
For a Life Free of Pain
Regenerative medicine company Regeneus is at the forefront of providing a novel, stem cell-based therapy for knee osteoarthritis which afflicts hundreds of millions of people worldwide.
Read MoreApple’s surveillance challenge, blockchain gaming capital raises, and the start of suborbital spaceflight sales
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreGenetic Signatures: Australia’s Rapid Growth Diagnostics Company
Genetic Signatures’ growth strategy is about building its customer numbers, the range of its proprietary tests for COVID-19 and a range of viral, protozoan, fungal and bacterial infections.
Read MoreMemphasys Taking on One of Humanity’s Most Pressing Issues
Humanity has a profound demographic problem and it’s not overpopulation. On the contrary, men are becoming more infertile and the quality of their sperm is deteriorating, leading to health problems.
Read MoreTime crystals, sodium-ion batteries, and where to go when civilisation collapses
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreThe Road Forward for Antisense
Managing Director and CEO Mark Diamond discusses the key highlights of the quarterly results for Antisense Therapeutics and other recent company news of note.
Read MoreInstitutions Support Immutep Capital Raising
Australian biotech company Immutep has announced it has completed the second tranche of its institutional placement at an issue price of A$0.52 per share to raise approximately A$46.3 million.
Read MoreOptical deep-learning, a potential grid-scale battery tipping point, and Chinese cybersecurity regulations
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreBiopharma’s Targeted Approach to Growth
Janus Henderson’s Andy Acker and Agustin Mohedas explain how a new drug targeting a common mutation found in tumours could benefit patients and biopharma alike.
Read MoreCancer vaccines, streaming market share, and the $1bn crypto-trading startup
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreAI-designed chips, a new self-driving competitor, and Bitcoin becomes legal tender
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreAlzheimer’s Decision Sends Positive Message to Aussie Biotechs
The US Food and Drug Administration’s approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude to green-lighting novel drugs for difficult-to-treat illnesses.
Read More